<sup>18</sup>F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

Ben‐Haim, Simona; Ell, Peter J.

doi:10.2967/jnumed.108.054205

Cited by 283 publications

(178 citation statements)

References 71 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…re lease large amounts of lac tate in vivo [259][260][261]. Al though stud ies on cell cul tures showed that mi to chon dr ial res pi ra tion is lim ited in sev eral can cer cell lines [262][263][264], in vivo data showed that mi to chon dr ial oxy gen con sump tion is not im paired in tu mors and that ox ida tive glu cose me tab o lism is re quired for tu mor growth [265].…”

Section: Metabolic Differences Between In Vitro and In Vivo Models Ofmentioning

confidence: 99%

Cancer metabolism in space and time: Beyond the Warburg effect

Danhier

Bański

Payen

et al. 2017

Biochimica et Biophysica Acta (BBA) - Bioenergetics

162

139

View full text Add to dashboard Cite

Available online xxx Keywords:Can cer Me tab o lism Mi to chon dria Het ero gene ity Metas ta sis A B S T R A C T Al tered me tab o lism in can cer cells is piv otal for tu mor growth, most no tably by pro vid ing en ergy, re duc ing equiv a lents and build ing blocks while sev eral metabo lites ex ert a sig nal ing func tion pro mot ing tu mor growth and pro gres sion. A can cer tis sue can not be sim ply re duced to a bulk of pro lif er at ing cells. Tu mors are in deed com plex and dy namic struc tures where sin gle cells can het ero ge neously per form var i ous bi o log i cal ac tiv i ties with dif fer ent meta bolic re quire ments. Be cause tu mors are com posed of dif fer ent types of cells with meta bolic ac tiv i ties af fected by dif fer ent spa tial and tem po ral con texts, it is im por tant to ad dress me tab o lism tak ing into ac count cel lu lar and bi o log i cal het ero gene ity. In this re view, we de scribe this het ero gene ity also in meta bolic fluxes, thus show ing the rel a tive con tri bu tion of dif fer ent meta bolic ac tiv i ties to tu mor pro gres sion ac cord ing to the cel lu lar con text. This ar ti cle is part of a Spe cial Is sue en ti tled Res pi ra tory com plex I, edited by Giuseppe Gas parre, Ro drigue Rossig nol and Pierre Son veaux. Abbreviations: ACL, ATP cit rate lyase; AMPK, adeno sine monophos phate ki nase; ARG1, L argi nine me tab o liz ing en zyme arginase 1; BCAA, branched chain amino acid; Bcl2, B cell lym phoma 2; CAF, can cer as so ci ated fi brob last; CIC, can cer ini ti at ing cell; COX2, cy tochrome ox i dase; CSC, can cer stem cell; CREB, cyclic adeno sine monophos phate re sponse el e ment bind ing pro tein; DEC1, dif fer en tially ex pressed in chon dro cytes 1; EMT, ep ithe lial to mes enchy mal tran si tion; FAK, fo cal ad he sion ki nase; FAS, fatty acid syn thase; FBP, fruc tose 1,6 bis pho s phate; FDG PET, [ F] flu o rodeoxyglu cose positron emis sion to mog ra phy; GAPDH, glyc er alde hyde 3 phos phate de hy dro ge nase; HIF 1, hy poxia ac ti vated fac tor 1; HK2, hex ok i nase 2; HMGB1, high mo bil ity group box 1; HU VEC, hu man um bil i cal vein en dothe lial cell; IFN γ, in ter feron gamma; LDH, lac tate de hy dro ge nase; MEF, murine em bry onic fi brob last; MET, mes enchy mal to ep ithe lial tran si tion; MRI, mag netic res o nance imag ing; mTORC1, mam malian tar get of ra pamycin com plex 1; NSCLC, non small cell lung can cer; OX PHOS, ox ida tive phos pho ry la tion; PDAC, pan cre atic duc tal ade no car ci noma; PHD, pro lyl hy drox y lase; pHe, ex tra cel lu lar pH; pHi, in tra cel lu lar pH; PK, pyru vate ki nase; PPP, pen tose phos phate path way; REDD1, reg u lated in de vel op ment and DNA dam age re sponse 1; RhoA, Ras ho molog gene fam ily, mem ber A; ROS, re ac tive oxy gen species; SASP, senes cence as so ci ated se cre tory phe no type; SCO2, syn the sis of cy tochrome ox i dase 2; SGK 1, serum and glu co cor ti coid reg u lated ki nase 1 Sirt1, sir tuin 1; TAM, tu mor as so ci ated macrophage; TIGAR, TP53 in duced gly col y ...

show abstract

Section: Metabolic Differences Between In Vitro and In Vivo Models Ofmentioning

confidence: 99%

Cancer metabolism in space and time: Beyond the Warburg effect

Danhier

Bański

Payen

et al. 2017

Biochimica et Biophysica Acta (BBA) - Bioenergetics

162

139

View full text Add to dashboard Cite

show abstract

“…treatment. [17]. Previously, PET was limited to image larger animal models [18] but with improvements in technology and imaging quality, it is increasingly being used on smaller animals.…”

Section: Macroscopic Imaging Techniquesmentioning

confidence: 99%

Imaging in animal models

Webb¹,

Yuan²,

Lemoine³

et al. 2016

Integr Cancer Sci Therap

View full text Add to dashboard Cite

Advances in imaging techniques have significantly improved the choices available for in vivo imaging of animal research, particularly in the field of oncology. Development of existing technology has led to major advances in the miniaturisation of imaging techniques such as MRI, PET and CT enabling higher resolution imaging of smaller animals. One of the emerging growth areas is optical imaging, such as bioluminescence and fluorescence as a noninvasive technique to image orthotopic tumours models in mice. Recent developments in microscopic imaging techniques allow high resolution imaging of cancer cells in vivo in animal models. Another growth area is the development of multimodal scanners such as CT-PET to overcome individual limitations of a modality and to provide greater detail of tumours. This review discusses the strengths and limitations of established methods as well as more recent developments in preclinical imaging.

show abstract

“…Oesophageal carcinoma is only one of the solid tumours and lymphomas that are studied with 18 F-FDG PET in order to assess tumour response to radiation and chemotherapy treatments, which has been recently summarized [11] in a literature review.…”

mentioning

confidence: 99%

Evaluation of response: is 18F-FDG PET the answer?

Chiti

2009

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

¹⁸F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

Cited by 283 publications

References 71 publications

Cancer metabolism in space and time: Beyond the Warburg effect

Cancer metabolism in space and time: Beyond the Warburg effect

Imaging in animal models

Evaluation of response: is 18F-FDG PET the answer?

Contact Info

Product

Resources

About

18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response

Cited by 283 publications

References 71 publications

Cancer metabolism in space and time: Beyond the Warburg effect

Cancer metabolism in space and time: Beyond the Warburg effect

Imaging in animal models

Evaluation of response: is 18F-FDG PET the answer?

Contact Info

Product

Resources

About

¹⁸F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response